Safety and efficacy of XXXX creation for the treatment of hepatic hydrothorax.

@entity1 @entity5273 @entity881
PURPOSE: To evaluate safety and efficacy of @entity5273 ( @entity5273 ) creation for hepatic hydrothorax (HHyd). MATERIALS AND METHODS: Twenty-one @entity1 underwent @entity5273 creation for HHyd. A prospective @entity5273 database and medical records were reviewed. Clinical and radiographic outcomes were recorded as complete (symptom/effusion resolution), partial (improved symptoms/effusion), or none. Data patterns were examined with chi(2) tests and Kaplan-Meier analysis. RESULTS: @entity1 included 12 @entity1 and nine @entity1 , with a mean age of 56 years, all with @entity1 class B (n = 7) or C (n = 14) disease. The technical success rate was 100%. Mean follow-up was 223 days. Twenty-nine percent (six of 21) died within 30 days of @entity5273 creation, 10% (two of 21) underwent transplantation within 30 days, and 62% (13 of 21) survived beyond 30 days. Data were incomplete in two @entity1 . Clinical response was classified as complete in 63% (12 of 19), partial in 11% (two of 19), and none in 26% (five of 19). Radiographic response was classified as complete in 30% (six of 20), partial in 50% (10 of 20), and none in 20% (four of 20). Nonresponders had @entity881 , and all but one died within 30 days. However, of the 13 @entity1 surviving longer than 30 days, 10 (77%) had a complete clinical response. CONCLUSION: @entity5273 is a relatively safe and effective method of controlling HHyd. The majority of @entity1 experienced improvement or resolution of clinical symptoms with a variable reduction in the quantity of pleural fluid. There was a tendency among nonresponders to die within 30 days.
